MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
NCT02399189
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG:
R-MT followed by auto-HSCT
Sponsor
Jun Zhu